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Abstract
Background: Traditional methods for analyzing clinical and epidemiological cohort study data have been focused
on the first occurrence of a health outcome. However, in many situations, recurrent event data are frequently
observed. It is inefficient to use methods for the analysis of first events to analyse recurrent event data.
Methods: We applied several semi-parametric proportional hazards models to analyze the risk of recurrent
myocardial infarction (MI) events based on data from a very large randomized placebo-controlled trial of
cholesterol-lowering drug. The backward selection procedure was used to select the significant risk factors in a
model. The best fitting model was selected using the log-likelihood ratio test, Akaike Information and Bayesian
Information Criteria.
Results: A total of 8557 persons were included in the LIPID study. Risk factors such as age, smoking status, total
cholesterol and high density lipoprotein cholesterol levels, qualifying event for the acute coronary syndrome,
revascularization, history of stroke or diabetes, angina grade and treatment with pravastatin were significant for
development of both first and subsequent MI events. No significant difference was found for the effects of these
risk factors between the first and subsequent MI events. The significant risk factors selected in this study were the
same as those selected by the parametric conditional frailty model. Estimates of the relative risks and 95%
confidence intervals were also similar between these two methods.
Conclusions: Our study shows the usefulness and convenience of the semi-parametric proportional hazards
models for the analysis of recurrent event data, especially in estimation of regression coefficients and cumulative
risks.
Background
Many clinical and epidemiological cohort studies involve
health outcomes that a participant of the study can
experience several times during the follow-up period.
Such outcomes are often termed recurrent or repeated
events [1,2]. For example, transient ischemic attacks can
occur repeatedly among patients with cerebrovascular
disease [3]. A person who is infected with HIV may
experience several opportunistic infections in HIV/AIDS
clinical trials [4]. However, traditional statistical meth-
ods for the analysis of cohort study data have been
focused on the first occurrence of an outcome [5]. It is
reasonable to assume that the first occurrences of an
outcome among different individuals are independent,
which is an important assumption in modelling these
events.
However, the methods for the analysis of first events
are inefficient in the analysis of recurrent event data
because of the possible correlation among recurrent out-
comes in an individual. An individual may be prone to
develop more recurrent events or the time interval
between these events may be shorter than others in the
study depending on the characteristics of the individual.
Therefore, the assumption of independence of the event
times in the first event analysis method is often violated
for recurrent event data. Updated analytical methods are
needed to account for the dependence of the repeated
measurements in a person during follow-up study.
Various statistical methods have been proposed for the
analysis of recurrent event data [6-9]. The conditional
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recurrent events using stratification techniques [8,10].
The gap time between two consecutive recurrent events
is usually used in a conditional model. The conditional
model can be used to estimate the rate of a subsequent
event given an individual has already had such an event
during follow-up. On the other hand, Cox-type regres-
sion models have been considered by Prentice et al [11]
and Andersen and Gill [12] in their seminal studies in
this area. Wei et al [13] proposed a novel semi-para-
metric proportional hazards model and Lin [14] pre-
sented general theory for this method. Semi-parametric
models have further been updated and applied by Pepe
and Cai [15] for time-dependent covariates, by Lawless
and Nadeau [16] for a robust method, and by Glidden
and Vittinghoff [17] for analyzing multicenter clinical
trial data. Wang and Chang [18] clarified two sampling
designs in a longitudinal study and devoted their
method to the design where the initial occurrence of an
event is used as the enrolment criterion and repeated
occurrences of the same event are observed during fol-
low-up. Pena et al [19] and Pena et al [20] also dis-
cussed the general class of semi-parametric models for
recurrent events. Metcalfe and Thompson [21] reviewed
and evaluated the semi-parametric model method in the
analysis of recurrent event data and concluded that the
application of this method to recurrent event data is
justified.
The aim of this study was to apply several semi-para-
metric models to the analysis of recurrent myocardial
infarction (MI) events in a large randomized placebo-
controlled clinical trial in Australia and New Zealand
[22,23]. We focused on investigating the significant risk
factors for both the first and recurrent MI events during
follow-up and examining whether there was significant
difference in their effects for the first and recurrent MI
events.
Methods
The LIPID study
The Long-term Intervention with Pravastatin in Ischae-
mic Disease (LIPID) study [22-24] was a double-blinded
randomized placebo-controlled trial of a cholesterol-
lowering drug, pravastatin (40 mg daily). The study was
undertaken in 9014 patients who were 31 to 75 years of
age at the time of randomization. They had a history of
myocardial infarction or hospitalization for unstable
angina 3-36 months previously and initial plasma total
cholesterol levels of 155 to 271 mg per deciliter (4.0 -
7.0 mmol/liter) and triglyceride levels < 445 mg/dl (5
mmol/L). Patients were followed up for a median of 6.0
years between 1990 and 1997. In the present analysis,
data from the 8557 patients (4286 randomized to receive
pravastatin and 4271 to receive placebo) who did not
have any missing baseline information were used, which
is consistent with a previous study [24]. The primary
pre-specified endpoint in the LIPID study was coronary
heart disease (CHD)-related death and for secondary
analyses, a composite of CHD death or non-fatal myo-
cardial infarction. Details of the study design have been
published previously [22,23].
The outcome variables in this present analysis were
the recurrence of an MI event during follow-up and the
time from randomization to each MI event. Explanatory
variables included gender (1 for males and 0 for
females), age at randomization (centered at 60 years for
ease of computing the baseline hazard rate), smoking
status (1 for smokers and 0 for non-smokers), total
serum cholesterol (centered at 5.0 mmol/l), high density
lipoprotein (HDL)-cholestero l( c e n t e r e da t1 . 0m m o l / l ) ,
treatment group (1 for pravastatin assignment and 0 for
placebo), qualifying acute coronary syndrome (ACS) at
baseline (unstable angina, single MI, or multiple MI
before randomization), coronary revascularization
(never, before the qualifying event, or after the qualify-
ing event but before randomization), dyspnea grade (0
for NYHA < III and 1 for NYHA ≥ III) based on New
York Heart Association definition [25], angina grade (0
for CCVS < III and 1 for CCVS ≥ III) based on the
Canadian Cardiovascular Society definition [26], dura-
tion of angina (0 for ≤5 years and 1 for >5 years), use of
aspirin (0 for no and 1 for yes), country of residence
(Australia or New Zealand), and history of stroke, dia-
betes mellitus or hypertension. Interactions between
these risk factors were also examined in the analysis.
The following multivariate regression models were
fitted to the data to incorporate all the above mentioned
explanatory variables. The backward selection method
was used to select the final model which includes risk
factors which were statistically significant at the 0.05
level.
Semi-parametric model
The semi-parametric model considered in this article is
an extension of the Cox proportional hazards model [5].
Suppose there are n participants in the study. For the
ith person (i =1 ,2 ,. . . ,n), the model is of the following
form
ht x ht x i
k
i
k
i
k
i
k () () () () ( | ) ( )exp[ ]  0  (1)
where ht i
k () () is the general hazard function and
ht i
k
0
() () is the baseline hazard function at time t for the
k
th recurrent event (k = 1, ..., K). The analysis time t is
calculated from the date of randomization to the date of
each recurrent MI event for each person in the study.
Both the risk factor x and the associated regression
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(k) are (p+1)-dimensional vectors, where p is
the number of covariates in the model. Parameter b
(k) is
estimated using the partial likelihood method [27]. The
advantage of using the semi-parametric model is that it
does not require explicit specification of the dependence
structure between the times of recurrent events of each
person; instead it uses the robust Huber/White sand-
wich estimator to obtain the variance of the estimated
regression coefficients [28-30]. The robust variance esti-
mator can be easily calculated using most of the stan-
dard statistical software packages. The cumulative risk
of a specific MI event after randomization can be calcu-
lated by
Ft Ht i
k
i
k () () () e x p [ () ] .   1
where Ht i
k () ()is the cumulative hazard by time t [31].
The censoring mechanism was assumed to be inde-
pendent of the recurrent event process, as it is in most
standard time-to-event analyses. A person was censored
if he/she died of non-cardiovascular causes, or was lost
to follow-up or was alive at the end of the study. There-
fore, a person might have several recurrent MI events,
or might not experience any MI event before being cen-
sored. Multiple data records might be observed for each
person for possible occurrence of an MI event or occur-
rence of censoring. However, the occurrence of an MI
was assumed not to influence the occurrence of censor-
ing, and vice versa, in the present analysis.
Model comparison
Several semi-parametric models were fitted to the LIPID
study data. Model 1 assumes that the covariate effect
b
(k) and the baseline hazard rate ht
k
0
() () were different
for the first and subsequent MI events. Model 2
assumes that the covariate effects b
(k) were the same for
the first and subsequent MI events but the baseline
hazard rates ht
k
0
() ()were different for these recurrent
events. Model 3 assumes that the covariate effects b
(k)
were different for the recurrent events but the baseline
hazard rates ht
k
0
() () were the same. Model 4 assumes
that both the covariate effects b
(k) and the baseline
hazard rates ht
k
0
() () w e r et h es a m ef o rt h er e c u r r e n t
events.
Model fitting
Appropriate data formats were prepared for fitting a
semi-parametric model. No matter how many observed
data records that a person can have, a total of K records
were created for each person in the study, where K was
the maximum number of recurrent events that were
experienced by all participants in the study. For a per-
son who had an MI event at time t, the value of the cor-
responding outcome was 1 for this time point. After the
time of the final MI event, the value of the outcome was
assumed to be 0 in order to make a total of K data
records. In addition, an indicator variable was created
for each data record of a person in the study. Details
concerning preparation of appropriate data formats can
be found in Therneau and Grambsch [8]. The statistical
analyses in this article were conducted using Stata soft-
ware version 10 [32], which allows semi-parametric
model analysis to be conducted easily with no specia-
lized programming required. These analyses were based
on the intention-to-treat principle where an individual
was assumed to take the treatment that was assigned to
him or her at the time of randomization [33].
Results
Follow-up in the LIPID Study
Table 1 shows the number of MI events and the out-
come status of participants at the end of the study.
A total of 870 MI events occurred in 745 patients (an
average of 1.2 events per person) during follow-up, of
whom 313 had been randomized to receive pravastatin
and 432 to receive placebo. In all, 7.3% (313/4286) of
the persons who were assigned to receive pravastatin
and 10.1% (432/4271) assigned to placebo had at least
one MI event during follow-up. The former proportion
was significantly lower than the latter (z =4 . 6 ,p <
0.001). The number of persons who had more than one
MI event during follow-up was generally low. About
0.9% (37/4286) of the persons in the pravastatin group
and 1.3% (56/4271) in the placebo group had more than
one MI event during follow-up. Because of the small
numbers of participants who had more than two MI
events in this study, the following analyses were focused
on the first two MI events, i.e. we assumed K=2in
model (1).
Table 1 Number of myocardial infarctions and outcome
status for the participants in the LIPID study
Variable Treatment
Pravastatin Placebo
Number of MI events
0 3973 3839
1 276 376
23 1 3 9
33 1 3
42 3
51 1
Outcome status
Died 470 592
Alive and had an MI event 236 305
Alive but no MI event 3580 3374
MI = myocardial infarction
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assigned pravastatin and 592 placebo) died during fol-
low-up. Another 541 patients (236 assigned pravasta-
tin, 305 placebo) experienced at least one MI event
during follow-up and were still alive at the end of the
study. The other 6954 patients (3580 assigned pravas-
tatin, 3374 placebo) did not experience any MI event
during follow-up and were still alive at the end of the
study.
Model comparison
Different semi-parametric models are compared in
Table 2. The same covariates were selected by all 4
models, which include age, smoking status, total cho-
lesterol and HDL cholesterol levels, qualifying ACS
event at baseline, coronary revascularization, history of
stroke or diabetes, angina grade and treatment with
pravastatin. Model 2 that has the same effect for all
recurrent events but with different baseline hazard
functions had the smallest AIC and BIC values, sug-
gesting that this model fitted the data better than
other three models. Model 1 that has different effects
for the recurrent events and different baseline hazard
functions had the second smallest AIC and BIC values.
The likelihood ratio test showed that there was no sig-
nificant difference between model 1 and model 2 (c
2 =
6.51, d.f. = 12, p = 0.89). On the other hand, model 4
that has the same effect for the recurrent events and
the same baseline function had the largest AIC and
BIC values, suggesting that this model had the poorest
f i tt ot h ed a t a .T h e r e f o r e ,m o d e l2w a sc o n s i d e r e dt o
be the best model.
Same effect model
Table 3 shows the significant risk factors and the esti-
mated hazard ratios and 95% confidence intervals as
specified in model 2. Specifically, compared with
patients in the placebo group, patients in the pravastatin
group had a 29% (95% CI 17 - 39%) reduction in the
risk for the both MI events. For one unit (mmol/l)
increase in total cholesterol level, the risk of an MI
event (both the first and second event) increased by 19%
(95% CI 9 - 30%); while for one unit (mmol/l) increase
in HDL-cholesterol, the risk of an MI event decreased
by 62% (95% CI 46 - 74%). Having a history of stroke
increased the risk of an MI event by 47% (95% CI 9 -
99%) and a history of diabetes increased the risk of an
MI event by 37% (95% CI 8 - 72%).
Similarly, compared with patients with unstable angina
as their qualifying event, the risk for an MI event during
follow-up was increased by 29% (95% CI 6 - 57%) in
those with a single MI event prior to randomization,
while patients with multiple MI events prior to rando-
mization had a 98% (95% CI 57 - 150%) increased risk.
Compared with patients without a history of coronary
revascularization, those who had revascularization before
randomization had a 59% (95% CI 26 - 101%) increased
risk for an MI event during follow-up; while patients
who had revascularization after the qualifying event and
before randomization had a 30% (15 - 42%) decreased
risk. Having an angina grade III also increased the risk
of an MI event during follow-up by 45% (95% CI 15 -
82%). Smoking also increased the risk of an MI event by
51% (95% CI 20 - 90%).
Table 2 Comparison of different semi-parametric models
in the LIPID study
Model Log-likelihood d.f. AIC BIC
Different baseline hazard
Model 1: Different effect -7317.331 24 14682.66 14868.61
Model 2: Same effect -7320.586 12 14665.47 14758.14
Same baseline hazard
Model 3: Different effect -7646.675 24 15341.35 15527.29
Model 4: Same effect -7915.245 12 15854.49 15947.46
AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion;
d.f. = degree of freedom
Table 3 Same effect model of the recurrent MI events in
the LIPID study
Risk factor Hazard ratio 95% CI P-value
Age (year) 1.02 1.01 - 1.03 <0.001
Smoking status
Non-smoker 1.0
Current smoker 1.51 1.20 - 1.90 <0.001
Total cholesterol 1.19 1.09 - 1.30 <0.001
HDL cholesterol 0.38 0.26 - 0.54 <0.001
Qualifying event for ACS
Unstable angina 1.0
Single MI 1.29 1.06 - 1.57 0.01
Multiple MI 1.98 1.57 - 2.50 <0.001
Revascularization
Never 1.0
Before ACS 1.59 1.26 - 2.01 <0.001
Since ACS 0.70 0.58 - 0.85 <0.001
History of stroke
No 1.0
Yes 1.47 1.09 - 1.99 0.01
Diabetes mellitus
No 1.0
Yes 1.37 1.08 - 1.72 0.009
Angina grade
CCVS < III 1.0
CCVS ≥ III 1.45 1.15 - 1.82 0.001
Treatment
Placebo 1.0
Pravastatin 0.71 0.61 - 0.83 <0.001
ACS = Acute Coronary Syndrome; CCVS = Canadian Cardiovascular Society
Class of angina; HDL = High Density Lipoprotein; MI = Myocardial Infarction.
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Table 4 shows the significant risk factors and the esti-
mates of hazard ratios and 95% confidence intervals as
specified in model 1. This model has different covariate
effects for the first and second recurrent MI events.
Based on the Wald test [34], there was no significant
difference in the effects of these risk factors between the
first and second MI events (p-values were between 0.076
and 0.91 in all cases). For example, compared with
patients in the placebo group, patients assigned pravas-
tatin had a 28% (95% CI 17 - 38%) reduction in the risk
for the first MI and 34% (95% CI 1 - 57%) reduction in
the risk of a second MI. Compared with patients with
unstable angina as their qualifying event, patients with
multiple MIs prior to randomization had a 92% (95% CI
54 - 140%) increased risk for a first MI event and 146%
(95% CI 34 - 354%) increased risk for a second MI dur-
ing follow-up.
Similarly, compared with patients who never had
revascularization, patients who had coronary revasculari-
zation before their qualifying acute coronary syndrome
had 54% (95% CI 23 - 92%) increased risk for a first MI
and 102% (95% CI 10 - 274%) increased risk for a sec-
ond MI during follow-up. Other risk factors (smoking
status, history of stroke or diabetes mellitus and angina
grade) significantly increased the risk for the first but
not the second MI event, probably due to the small
number of observed second MI events, but in no case
was there evidence of a different effect on first MI com-
pared to a second MI (Table 4).
F i g u r e1s h o w st h ec u m u l a t i v er i s ko fas p e c i f i cM I
event after randomization under model 2. For ease of
drawing this figure, baseline values of all significant
categorical variables and centralized values of all signifi-
cant continuous variables were used in model 2. These
values included non-smoking status, 60 years of age,
t o t a lc h o l e s t e r o ll e v e lo f1 9 3m g / d l( 5 . 0m m o l / l ) ,H D L
cholesterol level of 39 mg/dl (1.0 mmol/l), angina grade
III or less, previous unstable angina as the qualifying
acute coronary syndrome at baseline and no history of
revascularization, stroke or diabetes mellitus prior to
randomization. The cumulative risk of the first MI event
Table 4 Different effect model of the recurrent MI events in the LIPID study
Risk factor First MI event Second MI event Wald test
†
HR 95% CI P-value HR 95% CI P-value
Age (year) 1.02 1.01 - 1.03 <0.001 1.04 1.01 - 1.06 0.007 0.14
Smoking status
Non-smoker 1.0 1.0
Current smoker 1.49 1.20 - 1.85 <0.001 1.71 0.94 - 3.12 0.079 0.63
Total cholesterol 1.18 1.08 - 1.28 <0.001 1.34 1.08 - 1.66 0.007 0.21
HDL cholesterol 0.41 0.29 - 0.59 <0.001 0.17 0.06 - 0.47 0.001 0.076
Qualifying event for ACS
Unstable angina 1.0 1.0
Single MI 1.27 1.06 - 1.53 0.011 1.44 0.81 - 2.54 0.21 0.66
Multiple MI 1.92 1.54 - 2.40 <0.001 2.46 1.34 - 4.54 0.004 0.39
Revascularization
Never 1.0 1.0
Before ACS 1.54 1.23 - 1.92 <0.001 2.02 1.10 - 3.74 0.024 0.34
Since ACS 0.70 0.58 - 0.85 <0.001 0.65 0.36 - 1.16 0.14 0.76
History of stroke
No 1.0 1.0
Yes 1.50 1.12 - 2.00 0.006 1.31 0.57 - 3.04 0.53 0.75
Diabetes mellitus
No 1.0 1.0
Yes 1.40 1.12 - 1.75 0.003 1.14 0.58 - 2.23 0.70 0.53
Angina grade
CCVS < III 1.0 1.0
CCVS ≥ III 1.44 1.16 - 1.80 0.001 1.48 0.83 - 2.65 0.18 0.91
Treatment
Placebo 1.0 1.0
Pravastatin 0.72 0.62 - 0.83 <0.001 0.66 0.43 - 0.99 0.047 0.67
† P-value for Wald test. ACS = Acute Coronary Syndrome; CCVS = Canadian Cardiovascular Society Class of angina; HDL = High Density Lipoprotein;
MI = Myocardial Infarction.
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these baseline values was 3.6% if the person was
assigned to pravastatin and 5.1% if assigned to placebo.
The cumulative risk for a second MI event within 5
years of randomization was lower but there was a simi-
lar relative treatment effect, being 0.5% for pravastatin
and 0.7% for placebo.
Same baseline hazard model
We also fitted a semi-parametric model with the same
baseline hazard function for the first and second MI
events to the data. Compared with the estimated effects
in Tables 3 and 4, the estimated effects under this new
model increased slightly for the first MI event; while the
estimated effects for the second MI event decreased
slightly. The baseline cumulative risk in 5 years after
randomization was about 2.8% for patients assigned to
receive pravastatin and 3.6% for patients to receive
placebo.
First MI event model
Finally we fitted the traditional proportional hazards
model by considering only the first MI event in the ana-
lysis, as shown in Table 5. Because the number of obser-
v a t i o n si nt h i ss t u d yw a so n l yh a l fo ft h o s ei nT a b l e3
and 4, this model was not comparable directly with
those in Tables 3 and 4 using the AIC and BIC meth-
ods. However, the same significant explanatory variables
in Tables 3 and 4 were found to be statistically signifi-
cant for this model. The estimated effects of these risk
factors were the same as those given in Table 4 for the
first MI event.
Model Comparison
Compared with our previous analysis results under the
parametric frailty model [10], we found that the same
explanatory variables were selected into the final model
in this study by the same selection procedure. The esti-
mates of the regression coefficients and 95% confidence
intervals were also similar. For example, the estimate of
the smoking effect was 1.49 (95% CI 1.17 - 1.89) under
the parametric frailty model (Table 3 in [10]) compared
with 1.51 (95% CI 1.20 - 1.90) under the semi-para-
metric model (Table 3 in this article). Similarly, the esti-
mate of the treatment effect of pravastatin was 0.71
(95% CI 0.60 - 0.83) under the parametric frailty model
compared with 0.71 (95% CI 0.61 - 0.83) under the
semi-parametric model.
However, interpretation of the risk of a recurrent
event is different between the parametric conditional
model and the semi-parametric proportional hazards
model. The time period used to calculate the cumulative
risk under the parametric conditional model was the
time interval between two consecutive recurrent events;
while it was from randomization to each recurrent event
under the semi-parametric proportional hazards model.
Figure 1 Estimated baseline cumulative risk of myocardial infarction (MI) during follow-up for a non-smoking patient aged 60 years
with total cholesterol level 5.0 mmol/l, HDL cholesterol 1.0 mmol/l, angina grade less than III, with unstable angina as the qualifying
acute coronary syndrome and no history of revascularization, stroke or diabetes mellitus before randomization.
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(Figure 1 in [10]), the cumulative risk of a second MI
event within 5 years was estimated to be 10.3% and
7.6% for persons assigned to placebo and pravastatin,
respectively. However, under the semi-parametric pro-
portional hazards model, the corresponding risk was
estimated to be 0.7% and 0.5%, respectively. It is note-
worthy that the cumulative risk for the first MI event
was similar under these two models because the com-
m o nt i m eo r i g i nw a su s e di nb o t hm e t h o d s( 5 . 6 %a n d
4.1% under the parametric conditional model compared
with 5.1% and 3.6% under the semi-parametric propor-
tional hazards model).
Discussion
In this article, we applied several semi-parametric mod-
els [i.e., Wei, Lin and Weissfeld (WLW) models] to the
analysis of the risk of recurrent myocardial infarctions
in the LIPID study. We found that risk factors such as
age, smoking status, total cholesterol and HDL choles-
terol levels, the nature of the qualifying acute coronary
syndrome, coronary revascularization, history of stroke
or diabetes, angina grade and treatment with pravastatin
were significant in the development of an MI event dur-
ing follow-up. No significant difference was found in the
effects of these risk factors between the first and second
MI events. This is consistent with ongoing benefits of
pravastatin for patients after they have a first MI while
on active treatment. This analysis result is also consis-
tent with a previous study [24], which analyzed data
from the first MI and fatal coronary heart disease-
related death only.
A major concern about the WLW model is that each
individual is considered to be at risk of all recurrent
events from the start of the observation period, while
the conditional model [11] assumes that an individual is
at risk of the k
th event only if the person experienced
the (k-1)
th event. However, the WLW method has been
applied to recurrent event data because the nature of
the relationship between recurrent events needs not to
be known at the commencement of a study [6,14].
Furthermore, treatment effects are estimated based on
the comparison of treatment and placebo groups. The
WLW method is based on groups comparable at the
time of randomization [35,36].
It has been suggested that a fuller picture of the treat-
ment effect can be obtained from the application of
both the marginal and conditional models [14,37]. We
have published analysis results based on the conditional
model [10]. One aim of this article is to compare the
results of the marginal model with those from the con-
ditional model.
Comparison of our previous findings with the current
analysis shows that the semi-parametric models selected
the same explanatory variables compared with the para-
metric conditional frailty models. The estimates of the
regression coefficients and 95% confidence intervals
were also similar in the parametric and semi-parametric
models. However, interpretation of the risk of a recur-
rent event is different between the parametric condi-
tional model and the semi-parametric proportional
hazards model. Under the parametric conditional model,
the risk of a recurrent event is conditional on a person
having had an MI event. The time period for calculating
this risk is based on the gap between two consecutive
recurrent events. This study shows that the chance of
having two MI events within 5 years was low among all
participants in the LIPID study; while the previous ana-
lysis suggested that the chance of having another MI
event among a subset of participants who have already
had an MI event was moderate.
Both semi-parametric proportional hazards model and
the parametric conditional model are useful tools to
further explore the biological process of a medical con-
dition, such as different clinical manifestations of coron-
ary atherosclerosis, our most common major health
Table 5 First event model of the recurrent MI events in
the LIPID study
Risk factor Hazard ratio 95% CI P-value
Age (year) 1.02 1.01 - 1.03 <0.001
Smoking status
Non-smoker 1.0
Current smoker 1.49 1.20 - 1.86 <0.001
Total cholesterol 1.18 1.08 - 1.29 <0.001
HDL cholesterol 0.41 0.29 - 0.58 <0.001
Qualifying event for ACS
Unstable angina 1.0
Single MI 1.27 1.06 - 1.53 0.008
Multiple MI 1.92 1.55 - 2.39 <0.001
Revascularization
Never 1.0
Before ACS 1.54 1.24 - 1.90 <0.001
Since ACS 0.70 0.58 - 0.85 <0.001
History of stroke
No 1.0
Yes 1.50 1.12 - 2.00 0.007
Diabetes mellitus
No 1.0
Yes 1.40 1.12 - 1.74 0.003
Angina grade
CCVS < III 1.0
CCVS ≥ III 1.44 1.16 - 1.80 0.001
Treatment
Placebo 1.0
Pravastatin 0.72 0.62 - 0.83 <0.001
ACS = Acute Coronary Syndrome; CCVS = Canadian Cardiovascular Society
Class of angina; HDL = High Density Lipoprotein; MI = Myocardial Infarction.
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Page 7 of 9problem. They allow examination of the sequential
occurrence of related events over time. The magnitude
and direction of the impact of potential risk factors on
these multiple events can also be examined using this
approach. Additionally, the relative importance of the
predictive values of a risk factor can be compared for
different events. It is noteworthy that age, total choles-
terol and HDL cholesterol were significant predictors of
recurrent as well as the first myocardial infarction dur-
ing follow-up.
The WLW method has been criticized because of its
failure to accommodate the ordered nature of the recur-
rent events, that is, an individual can be at risk for the
k
th event before the person experienced the (k-1)
th
event [38]. Essentially the WLW method assumes that
the treatment effect on event k will be “carried over” to
subsequent events, which may possibly cause biased esti-
mates of the treatment effects for the later events [39].
According to the definition of the risk set of the WLW
method, the occurrence of the first event also influences
the time spent at risk for subsequent events though
there is no direct treatment effect on the later events.
Another common criticism of the WLW method is
that there is no simple joint distribution of all event
times to satisfy the proportional hazards assumption
[38]. Finally, the WLW method has been criticised for
its failure to model the within-subject association of the
recurrent events directly, which could possibly result in
inefficient estimation of the treatment effect. However,
this issue is balanced by the easy implementation of the
robust variance estimates for any possible model mis-
specification.
Pravastatin has been shown to decrease coronary
events in a number of studies. A similar reduction in
risk of coronary heart disease death or nonfatal myocar-
dial infarction was observed in the Cholesterol and
Recurrent Events (CARE) study [40] and the LIPID
study [22-24]. The first occurrence of a nonfatal MI or
coronary heart disease death was considered in these
analyses [24,41], although other endpoints have been
included in other studies [41,42]. In this article,
advanced statistical methods were applied to analyze the
treatment effect of pravastatin for recurrent myocardial
infarctions. The analyses suggest that the treatment
effect of pravastatin was significant not only for the first
MI event, but also the second MI event during follow-
up. Furthermore the magnitude of the treatment effect
was similar for first and second events.
There are some limitations in this study. Insufficient
statistical power may have limited examination of the
importance of the conventional risk factors. The non-
significance of the effects of some risk factors for the
second MI event could be related to the smaller number
of second MI events during follow-up. Greater statistical
power can be achieved by expanding the outcome to
include other frequently observed endpoints, such as
unstable angina or the need for coronary revasculariza-
tion (percutaneous coronary intervention or coronary
artery bypass graft surgery). Another potential limitation
is that we did not consider the possibility of informative
censoring of a fatal event which would preclude the
occurrence of possible future MI events [2,4,39,43-45].
Joint modeling of recurrent events including a possible
fatal event is needed in future investigation.
Conclusions
In conclusion, we found that the application of semi-
parametric proportional hazards model to the analysis
of recurrent event data is informative and convenient,
especially in the estimation of regression coefficients
and cumulative risks. The treatment effect of pravastatin
was similar on first and subsequent MI events. Impor-
tant baseline characteristics showed no evidence of dif-
ferent predictive abilities between first and subsequent
events.
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